The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I agree the market cap is/was too cheap, but I can't see the justification for it doubling on the back of this CBD tie up.
on what basis are they saying 35p?
hope so. this has been dead money for me over the past 12 months. My personal view is that the 2020 numbers will yet again be uninspiring. Hopefully the outlook for 2021 will be better. You can have the best tech in the world, but.......
Mr pr - started buying around 30p but average now £1.20. I’m not planning on selling any for a long time yet. You only get an opportunity like this once in a generation. At one time I did hold more but had to sell some to pay my tax bill end of Jan. Thanks to everyone for all their research and comments on here. I doubt I would have held my nerve without reading some of the well informed comments on here. I don’t post much, but read everything. Thanks and good luck everyone
Same here. Always knew affimers would deliver great results. Anyone who’d done their research should have felt pretty confident. Absolutely delighted. Holding 550k shares and can say “told you so” to the losers that said I should sell
EyeGuy - "I personally cannot think of a more valuable pharma product in recent history"
Agreed, but only if it works, which we don't know currently and that's the biggest risk and reflected in the current market cap.
If we get confirmation it works, then there are no limits on how high this could go.
https://www.thestreet.com/video/jim-cramer-says-home-tests-necessary-next-level-economic-recovery
has anyone told him about Avacta? https://www.thestreet.com/video/jim-cramer-says-home-tests-necessary-next-level-economic-recoveryIf only we had a test.....
pathetic. makes me so angry the dimwits that think they can make a quick buck. do some research before you invest. clearly stocks are not for you. no sympathy whatsoever with people like you. people like you are making a mockery of investing in stocks. go back you your savings account and premium bonds.
mowzerrocks - I agree. Also, PI's are selling their AIM stocks and piling in to GameStop, AMC, Blackberry etc. It's having a knock on effect. crazy
The problem here is that initial Scally results have been hyped up big time. You don't need to scroll back far to see that. In reality, it takes time to develop these prospects. Patience will be rewarded. I still hold 12m and have no plans to sell any, at least for the next 3-5 years. Hold for gold..
clearly not the RNS everyone was hoping for, but patience will be rewarded for those with a long term view.
wow. that was enlightening. thanks for sharing.
current market cap at 0.6 is roughly £200m. At 6p £2b. at 60p £20b. at 600p £200b. To suggest this is going to £10 is absolutely ridiculous. 6p over the next 24 months, maybe.
Not sure if this has been posted already and/or discussed here, but I received this email at my work address today;
Now available from stock at £400+VAT for a box of 20!
Give your patients, their families, your supporters or visitors peace of mind with this rapid 15 minute COVID-19 test from Siemens.
PHE Approved
The Cinitest rapid covid-19 antigen test has successfully passed the Department of Health and Social Care (DHSC) futility testing process defined by the UK government.
CE Marked
CE marked in accordance with Directive 98/79/EC on in vitro diagnostic medical devices (see Certificate of Conformity)
Product Information
Identifying infected COVID-19 patients is crucial in containing and preventing the spread of this disease. Fast, accessible and scalable the lateral flow CLINITEST® Rapid COVID-19 Antigen Test is visually read and easy to use, with results in just 15 minutes.
The CLINITEST Rapid COVID-19 Antigen Test is easy to administer for healthcare professionals and delivers results quickly using the nasopharyngeal swab method. Once a sample is collected, the swab is inserted into a tube with a special liquid to extract the target molecule. This liquid is then dispensed onto a test cassette and, in 15 minutes, a positive or negative result is clearly indicated.
No specialised personnel, equipment, or analysers are required—the test can be administered anywhere, anytime by trained professionals. The results should be interpreted by a trained and qualified healthcare professional.
With a specificity of 99.22% and sensitivity of 96.72%, you can feel confident in reliable results. Studies performed by the developer (across a number of sites, clinical environments, and operators) demonstrated high-quality performance data.
When used as part of a comprehensive strategy, the CLINITEST Rapid COVID-19 Antigen Test can help communities get ahead of the spread.
Specifications:Test time: 15 minutes
Sample type: nasopharyngeal
Storage: room temperature or refrigerated (2?30° C)
Long Shelf Life
do we think this is being walked down to allow institutional buying? Interested in people's thoughts.
So frustrating. Here we have a therapeutic which clearly has demonstrated amazing results, albeit with a smallish sample. You would think that with 10+ years of development and various trials, all of which showed the drug to be safe, that they would approve this for emergency use. It seems that there is one rule for vaccines and another for small pharma developing ground breaking therapeutics.
I think you have to look past the day to day volatility. When a stock trades at a fraction of a penny, it can be very easily manipulated and also any movements can disproportionate to the share price.
11am I believe.
eastender1 - let's hope so!